Dolutegravir + Rilpivirine 50 mg / 25 mg Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 50 mg / 25 mg
Reference Brands: Juluca(EU & US)
Category: Anti Viral
Dolutegravir + Rilpivirine, sold as Juluca, is a once-daily, two-drug HIV-1 maintenance therapy for virologically suppressed adults. It offers effective viral suppression with fewer side effects and is approved by the FDA and EMA.
Product Description:
Dolutegravir + Rilpivirine, marketed as Juluca, is a once-daily, two-drug regimen for the maintenance treatment of HIV-1 infection. It combines Dolutegravir, an integrase strand transfer inhibitor (INSTI), and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), to effectively suppress HIV replication. Approved by the US FDA and EMA, Juluca is intended for adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure. Juluca offers a simplified treatment option with fewer drugs, reduced side effects, and excellent tolerability, making it ideal for long-term HIV management.
Dolutegravir + Rilpivirine — third party manufacturing & bulk supply
Dolutegravir + Rilpivirine 50 mg / 25 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Dolutegravir + Rilpivirine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Dolutegravir + Rilpivirine →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Dolutegravir and rilpivirine are used together as a complete two-drug regimen for the treatment of HIV-1 infection in adults. It is prescribed for patients who are already virologically suppressed on a stable antiretroviral therapy and want to switch to a simpler regimen. The combination maintains viral suppression and helps reduce pill burden.
It is made from Dolutegravir, an integrase strand transfer inhibitor, and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor. Together, these two agents block HIV replication through different mechanisms, providing effective dual therapy.
The trade name for this combination is Juluca.
Juluca is manufactured by ViiV Healthcare in collaboration with Janssen Therapeutics, which provides the rilpivirine component.
The generic name is Dolutegravir + Rilpivirine.
The brand name is Juluca.
It is manufactured in the UK and Europe by ViiV Healthcare, with global distribution, and generic versions are produced in India by licensed manufacturers for developing markets.
Related Products
Brincidofovir
Strength:
100 mg, 10 mg/ml
Form: Tablets / Oral suspension
Reference Brands: Tembexa (USA/EU)
View Details
Lenacapavir
Strength:
300 mg, 463.5 mg/1.5 mL
Form: Tablet / Injection
Reference Brands: Yeztugo (USA), Sunlenca (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
